MipTec is the largest drug discovery conference in Europe with over 3,000 delegates from pharmaceutical companies
Stem Sells, Translational Medicine, Protein Therapeutics, Medicinal Chemistry and others
New in silico approaches to evaluating the efficacy of and repurposing drugs for aging and age-related diseases
The forum will attract many young scientists in aging research providing the possibility to recruit scarse talent with unique skills and interests
Unlike other aging conferences, the forum is geared towards the pharmaceutical industry addressing the need for new markers and new drugs within the traditional regulatory frameworks
Tuesday, May 3, 2016
Wednesday, April 6, 2016
Alex Zhavoronkov, PhD, CEO of Insilico Medicine will present a range of deep learned biomarkers of ageing and deep learned predictors of biological age at the RE-WORK Deep Learning in Healthcare Summit in London, 7-8th of April. The first such predictor is already available online at http://www.
"RE-WORK summits are clearly outperforming most industry conferences in agility, openness, diversity and focus on applications of deep learning in multiple areas and we are happy to be invited to present at their Deep Learning in Healthcare Summit in London. Artificial intelligence will transform biomarker development and drug discovery much sooner than most pharmaceutical companies and regulators expect and we are happy to be at the forefront of this emerging trend", said Alex Zhavoronkov, PhD, CEO or Insilico Medicine, Inc.
The Pharmaceutical Artificial Intelligence division of Insilico Medicine is providing a broad range of machine learning services in biomarker development, drug discovery and high-throughput screening optimization to some of the most innovative pharmaceutical and biotechnology companies. In 2015 scientists at Insilico Medicine published over 20 research papers in reputable academic journals.
"While our main project is related to applying artificial intelligence to identify and personalize Geroprotectors, interventions that slow down or reverse human biological aging, we have a solid pipeline of pharma and biotechnology research projects that help us fund our own research, gain unique expertise and establish reputation as a trusted partner. If you are reading this, please follow us on PubMed or ResearchGate and consider collaborating with our team and please attend our conferences in St. Petersburg and Basel", said Alex Aliper, president of Insilico Medicine, Inc.
Tuesday, April 5, 2016
Studies reach conflicting conclusions on GDF11 as a rejuvenating factor.
The GlaxoSmithKline group treated skeletal muscle satellite cells from older mice with GDF11, but did not see increased activity as Wagers and Lee had reported. Administering the protein to young mice resulted in a reduction of lean mass as well, the team noted.
These latest results fall more in line with a 2015 study from the Novartis Institutes for Biomedical Research than with those reported by the Harvard team. But Lee and collaborators later produced evidence that the discrepancy between their results and the Novartis findings was due to reagents. “I think a lot of this is, early on in the field the reagents aren’t perfect, the assays aren’t perfect, so people get results that look like they’re opposing each other,” Lee told The Scientist in October 2015. “We need better assays, we need more science, we really just need to do more work.”
Indeed, the debate over GDF11’s role in aging is far from settled. In a pair of commentaries in the April issue of Circulation Research, the Lee/Wagers group and a separate team, led by Steven Houser of Temple University, laid out the evidence for GDF11’s functions and attempt to explain the discrepancies between different labs’ results.
“The data from the Lee/Wagers groups, and the associated media coverage, have given hope to aged individuals with cardiac, skeletal muscle, and central nervous system dysfunction,” Houser and colleagues wrote. “However, there is now sufficient concern about these data and we hope that any proposed rGDF11 clinical trials will do no harm".
Keywords: Anti aging; Heart; gdf11; Regeneration
Miracle Drug Metformin May Hold Longevity Secrets
Researchers at Cardiff University found that this anti-aging drug, called Metformin, could extend our life spans to in the 100s, according to the New Zealand Herald.
“If you target an ageing process and you slow down ageing then you slow down all the diseases and pathology of ageing as well. That’s revolutionary. That’s never happened before,” said Professor Gordon Lithgow of the Buck Institute for Research on Ageing in California.
The drug, which is commonly used by diabetic patients, costs less than a dollar to manufacture, according to The Telegraph, and was first tested on roundworms by Belgian scientists, yielding encouraging results.
The drug helps the progression of certain diseases in the body slow down–boosting longevity and overall health and wellness. It also helps increase oxygen flow on the cellular level, which, in turn, slows, cell division and keeps the body functioning properly by reducing age-related changes, according to Fox News.
Now, the U.S. Food and Drug Administration is working to proceed with a clinical trial that will begin as early as next year, involving 3,000 participants between the ages of 70 and 80 from various U.S. locations. The trial is expected to run for five to seven years.
Keywords: Ageing; Research; Metformin; FDA.
Wednesday, March 16, 2016
Tuesday, March 15, 2016
Sunday, February 28, 2016
Findings may also lead to a greater understanding of how other organs in the body age, which could pave the way for drug developments in a number of age-related diseases, including cancer.
For the first time, scientists have identified the activity of a metabolic enzyme found in the batteries of human skin cells as being key to the declines of aging.